Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Mining Enters Drug Target Discovery Collaboration with Cytochroma

NEW YORK, May 1 - Molecular Mining is using its data mining software in a collaboration with Cytochroma, a Canadian company that uses genomic information to identify and develop drugs that target cytochrome p450 enzymes, the companies said Tuesday.

Under the arrangement, Molecular Mining is employing the software in a search for novel genes to serve as potential drug targets for Cytochroma. Molecular Mining has already identified hundreds of gene sequences that are homologous to cytochrome p450 sequences, Cytochroma said.

Cytochroma is paying an undisclosed fee to Molecular Mining, as well as "some sharing of the upside of things," in the event that gene-based drug targets yield marketable therapeutic candidates, said Robert Foldes, CEO of Cytochroma. The collaboration is open-ended, and will last for "as long as we want to explore genomes," Foldes added.

Cytochroma of Kingston, Ontario, decided to partner with Molecular Mining, because the company is located nearby, also in Kingston, and because its scientists were able to work with Cytochroma to develop custom algorithms based on Cytochroma's knowledge of p450 sequences, according to Foldes. The algorithms are based on a Hidden Markov model, Foldes said.

"Our collaboration with Molecular Mining has already yielded important insights into the complement of human genes that encode this family of enzymes," said Martin Petkovich, co-chief scientific officer of Cytochroma, in a statement. "What we have also gained from mining the human  genome is a means to tap into the genomes of other organisms of medical relevance including fungi, parasites, bacteria etc. The potential to identify new and valuable cytochrome P450 based drug targets is enormous."

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.